Status: Recruiting
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
Participants needed: 220
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Bold Therapeutics, Inc.Updated: May 18, 2026Locations: 24
Eligibility criteria
Be 18 years or older. [+9]
Neuropathy > grade 2 [+19]